Key Points
-
The medical assessment of living kidney donor candidates can include additional investigations beyond the minimal recommended requirements to select candidates at lowest risk of renal and cardiac complications following donation
-
Measured glomerular filtration rate by isotopic methods provides a more accurate assessment of renal function than calculations of estimated glomerular filtration rate (eGFR), but might not be necessary for a large proportion of donor candidates who have acceptable eGFR values
-
Persistent isolated microscopic haematuria should be investigated to exclude urologic and glomerular diseases and might reveal abnormalities that would preclude donation
-
Donor candidates who are at low risk of perioperative cardiac events following nephrectomy do not need to undergo additional cardiac assessment
Abstract
Living kidney donation provides the best therapeutic outcomes for eligible patients with end-stage renal disease. To ensure suitability for living kidney donation, donor candidates undergo a thorough medical, surgical, and psychosocial evaluation by a multidisciplinary transplant assessment team. Numerous guidelines are available to assist clinicians in the process of donor evaluation and selection. These guidelines outline the minimum recommended requirements for donor screening and additional tests that are indicated when abnormalities arise; however, evidence suggests that some of these additional tests might not be required in certain donor candidates. Measured glomerular filtration rate (GFR) using isotopic methods is more accurate than estimated GFR for the assessment of renal function; however, a new clinical tool might enable the identification of donor candidates for whom nuclear medicine renal scans are not needed. Persistent isolated microscopic haematuria caused by urologic or glomerular diseases can preclude donation and such abnormalities can often be identified by kidney biopsy. Cystoscopy might not be useful for young patients, however, owing to the rarity of urological cancers in this population. Currently, no evidence exists to support the notion that donor candidates at low-risk of cardiac events should undergo additional preoperative cardiovascular evaluation before donation. Reducing and/or eliminating the need for additional testing has the potential to enhance efficiency in the donor evaluation process, improve patient satisfaction, and increase access to living donor kidney transplantation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Segev, D. L. et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 303, 959–966 (2010).
Lin, J., Kramer, H. & Chandraker, A. K. Mortality among living kidney donors and comparison populations. N. Engl. J. Med. 363, 797–798 (2010).
Fehrman-Ekholm, I., Elinder, C. G., Stenbeck, M., Tydén, G. & Groth, C. G. Kidney donors live longer. Transplantation 64, 976–978 (1997).
Lentine, K. L. & Segev, D. L. Understanding and communicating medical risks for living kidney donors: a matter of perspective. J. Am. Soc. Nephrol. 28, 12–24 (2017).
Lam, N. N., Lentine, K. L., Levey, A. S., Kasiske, B. L. & Garg, A. X. Long-term medical risks to the living kidney donor. Nat. Rev. Nephrol. 11, 411–419 (2015).
Delmonico, F. A. Report of the Amsterdam Forum on the care of the live kidney donor: data and medical guidelines. Transplantation 79, S53–S66 (2005).
Andrews, P. A., Burnapp, L., Manas, D., Bradley, J. A. & Dudley, C. Summary of the British Transplantation Society/Renal Association UK guidelines for living donor kidney transplantation. Transplantation 93, 666–673 (2012).
Abramowicz, D. et al. European Renal Best Practice guideline on kidney donor and recipient evaluation and perioperative care. Nephrol. Dial. Transplant. 30, 1790–1797 (2015).
Richardson, R. et al. Kidney paired donation protocol for participating donors 2014. Transplantation 99, S1–S88 (2015).
Tong, A., Chapman, J. R., Wong, G., de Bruijn, J. & Craig, J. C. Screening and follow-up of living kidney donors: a systematic review of clinical practice guidelines. Transplantation 92, 962–972 (2011).
Lentine, K. L. et al. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the evaluation and care of living kidney donors. Transplantation (in press).
Ferriman, A. Becoming a live kidney donor. BMJ 336, 1374–1376 (2008).
Sanner, M. A. The donation process of living kidney donors. Nephrol. Dial. Transplant. 20, 1707–1713 (2005).
Agerskov, H., Ludvigsen, M. S., Bistrup, C. & Pedersen, B. D. Living kidney donors' experiences while undergoing evaluation for donation: a qualitative study. J. Clin. Nurs. 24, 2258–2267 (2015).
LaPointe Rudow, D. et al. Consensus conference on best practices in live kidney donation: recommendations to optimize education, access, and care. Am. J. Transplant. 15, 914–922 (2015).
Moore, D. R. et al. Living donor kidney transplantation: improving efficiencies in live kidney donor evaluation — recommendations from a consensus conference. Clin. J. Am. Soc. Nephrol. 10, 1678–1686 (2015).
Garg, A. X. et al. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 70, 1801–1810 (2006).
Kasiske, B. L. et al. A prospective controlled study of living kidney donors: three-year follow-up. Am. J. Kidney Dis. 66, 114–124 (2015).
Fehrman-Ekholm, I. et al. Incidence of end-stage renal disease among live kidney donors. Transplantation 82, 1646–1648 (2006).
Ibrahim, H. N. et al. Long-term consequences of kidney donation. N. Engl. J. Med. 360, 459–469 (2009).
Cherikh, W. S. et al. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am. J. Transplant. 11, 1650–1655 (2011).
Mjøen, G. et al. Long-term risks for kidney donors. Kidney Int. 86, 162–167 (2014).
Muzaale, A. D. et al. Risk of end-stage renal disease following live kidney donation. JAMA 311, 579–586 (2014).
Lam, N. N., Lentine, K. L. & Garg, A. X. End-stage renal disease risk in live kidney donors: what have we learned from two recent studies? Curr. Opin. Nephrol. Hypertens. 23, 592–596 (2014).
Rizvi, S. A. H. et al. Long-term safety of living kidney donation in an emerging economy. Transplantation 100, 1284–1293 (2016).
Grams, M. E. et al. Kidney-failure risk projection for the living kidney-donor candidate. N. Engl. J. Med. 374, 411–421 (2016).
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
Bhuvanakrishna, T. et al. Comparison of estimated GFR and measured GFR in prospective living kidney donors. Int. Urol. Nephrol. 47, 201–208 (2015).
Delanaye, P. & Glassock, R. J. Kidney-failure risk projection for the living kidney-donor candidate. N. Engl. J. Med. 374, 2093–2094 (2016).
Lujan, P. R. et al. CKD-EPI instead of MDRD for candidates to kidney donation. Transplantation 94, 637–641 (2012).
Soveri, I. et al. Measuring GFR: a systematic review. Am. J. Kidney Dis. 64, 411–424 (2014).
Stevens, L. A. & Levey, A. S. Measured GFR as a confirmatory test for estimated GFR. J. Am. Soc. Nephrol. 20, 2305–2313 (2009).
Wahba, R. et al. Computed tomography volumetry in preoperative living kidney donor assessment for prediction of split renal function. Transplantation 100, 1270–1277 (2016).
OPTN/UNOS. Organ Procurement & Transplantation Network Policy 14: living donation. OPTN https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf (2016).
European Renal Best Practice Transplantation Guideline Development Group. ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol. Dial. Transplant. 28 (Suppl. 2), ii1–ii71 (2013).
Cohney, S., Kanellis, J. & Howell, M. The CARI guidelines. Donor renal function. Nephrology (Carlton) 15 (Suppl. 1), S137–S145 (2010).
Huang, N. et al. Estimated GFR for living kidney donor evaluation. Am. J. Transplant. 16, 171–180 (2016).
Gaillard, F. et al. Estimated or measured GFR in living kidney donors work-up? Am. J. Transplant. 16, 3024–3032 (2016).
Ierino, F. & Kanellis, J. The CARI guidelines. Donors at risk: haematuria. Nephrology (Carlton) 15 (Suppl. 1), S111–S113 (2010).
Jaffe, J. S., Ginsberg, P. C., Gill, R. & Harkaway, R. C. A new diagnostic algorithm for the evaluation of microscopic hematuria. Urology 57, 889–894 (2001).
Kelly, J. D., Fawcett, D. P. & Goldberg, L. C. Assessment and management of non-visible haematuria in primary care. BMJ 338, a3021 (2009).
Suzuki, Y. et al. Indication of cystoscopy in patients with asymptomatic microscopic haematuria. Scand. J. Urol. Nephrol. 34, 51–54 (2000).
Hole, B., Whittlestone, T. & Tomson, C. Investigating asymptomatic invisible haematuria. BMJ 349, g6768 (2014).
McGregor, D. O., Lynn, K. L., Bailey, R. R., Robson, R. A. & Gardner, J. Clinical audit of the use of renal biopsy in the management of isolated microscopic hematuria. Clin. Nephrol. 49, 345–348 (1998).
Shen, P., He, L., Jiang, Y., Wang, C. & Chen, M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria. Int. J. Clin. Pract. 61, 789–794 (2007).
Kido, R. et al. Persistent glomerular hematuria in living kidney donors confers a risk of progressive kidney disease in donors after heminephrectomy. Am. J. Transplant. 10, 1597–1604 (2010).
Packham, D. K. Thin basement membrane nephropathy and IgA glomerulonephritis: can they be distinguished without renal biopsy? Nephrology (Carlton) 12, 481–486 (2007).
Donadio, J. V. & Grande, J. P. IgA nephropathy. N. Engl. J. Med. 347, 738–748 (2002).
Muzaale, A. D. et al. Outcomes of live kidney donors who develop end-stage renal disease. Transplantation 100, 1306–1312 (2016).
Anjum, S. et al. Patterns of end-stage renal disease caused by diabetes, hypertension, and glomerulonephritis in live kidney donors. Am. J. Transplant. 16, 3540–3547 (2016).
Tomson, C. R. V. Indications for renal biopsy in chronic kidney disease. Clin. Med. 3, 513–517 (2003).
Koushik, R., Garvey, C., Manivel, J. C., Matas, A. J. & Kasiske, B. L. Persistent, asymptomatic, microscopic hematuria in prospective kidney donors. Transplantation 80, 1425–1429 (2005).
Sobh, M. A., Moustafa, F. E., el- Din Saleh, M. A., Tawfik, A. & Ghoneim, M. A. Study of asymptomatic microscopic hematuria in potential living related kidney donors. Nephron 65, 190–195 (1993).
Choi, S. R. et al. The role of kidney biopsy to determine donation from prospective kidney donors with asymptomatic urinary abnormalities. Transplant. Proc. 44, 11–13 (2012).
Hassan, E., Aleid, H., Zulfiquar, T., Ibrahim, I. & Almana, H. Potential kidney donors with asymptomatic microscopic hematuria: histopathological findings & outcomes. Am. J. Transplant. 16 (Suppl. 3), 203–404 (2016).
Schold, J. D. et al. Comorbidity burden and perioperative complications for living kidney donors in the United States. Clin. J. Am. Soc. Nephrol. 8, 1773–1782 (2013).
Schold, J. D. et al. Hospitalizations following living donor nephrectomy in the United States. Clin. J. Am. Soc. Nephrol. 9, 355–365 (2014).
Lentine, K. L. et al. Perioperative complications after living kidney donation: a national study. Am. J. Transplant. 16, 1848–1857 (2016).
Moody, W. E. et al. Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors? J. Hum. Hypertens. 26, 141–148 (2012).
Garg, A. X. et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ 344, e1203 (2012).
Reese, P. P. et al. Mortality and cardiovascular disease among older live kidney donors. Am. J. Transplant. 14, 1853–1861 (2014).
Ierino, F., Boudville, N. & Kanellis, J. The CARI guidelines. Donors at risk: hypertension. Nephrology (Carlton) 15 (Suppl. 1), S114–S120 (2010).
Boudville, N. & Isbel, N. The CARI guidelines. Donors at risk: impaired glucose tolerance. Nephrology (Carlton) 15 (Suppl. 1), S133–S136 (2010).
Isbel, N. The CARI guidelines. Donors at risk: obesity. Nephrology (Carlton) 15 (Suppl. 1), S121–S132 (2010).
Fleisher, L. A. et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 64, e77–e137 (2014).
Lee, T. H. et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100, 1043–1049 (1999).
Devereaux, P. J. et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 173, 627–634 (2005).
Dakik, H. A., Kobrossi, S. & Tamim, H. The yield of routine pre-operative cardiovascular evaluation in stable patients scheduled for elective non-cardiac surgery. Int. J. Cardiol. 186, 325–327 (2015).
Taler, S. J. et al. Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades. Am. J. Transplant. 13, 390–398 (2013).
Hewing, B. et al. Midterm echocardiographic follow-up of cardiac function after living kidney donation. Clin. Nephrol. 83, 253–261 (2015).
Moody, W. E. et al. Cardiovascular effects of unilateral nephrectomy in living kidney donors. Hypertension 67, 368–377 (2016).
Acknowledgements
N.N.L. is supported by the Kidney Research Scientist Core Education and National Training Program (KRESCENT) New Investigator award. K.L.L. is supported by a grant from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), “Long-Term Health Outcomes After Live Kidney Donation in African Americans” (R01-DK096008). A.X.G. received an investigator-initiated grant from Astellas to support a Canadian Institutes of Health Research study in living kidney donors, and his institution has received unrestricted research funding from Pfizer. He is supported by the Dr Adam Linton Chair in Kidney Health Analytics.
Author information
Authors and Affiliations
Contributions
N.N.L. researched the data for the article. All authors contributed substantially to discussion of the article's content, writing, and review or editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
A.X.G. has received funding from Astellas, and his institution has received unrestricted research funding from Pfizer. The other authors declare no competing interests.
Related links
DATABASES
PowerPoint slides
Glossary
- Revised Cardiac Risk Index
-
(RCRI). The RCRI includes the following risk factors to assess the risk of perioperative cardiac death, non-fatal myocardial infarction, and non-fatal cardiac arrest: history of ischaemic heart disease, congestive heart failure, cerebrovascular disease, diabetes mellitus requiring insulin, chronic kidney disease (serum creatinine >177 μmol/l (>2 mg/dl)), and high-risk surgery (supra-inguinal vascular, intra-peritoneal, or intra-thoracic surgery).
Rights and permissions
About this article
Cite this article
Lam, N., Lentine, K. & Garg, A. Renal and cardiac assessment of living kidney donor candidates. Nat Rev Nephrol 13, 420–428 (2017). https://doi.org/10.1038/nrneph.2017.43
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.43
This article is cited by
-
Optimizing Efficiency in the Evaluation of Living Donor Candidates: Best Practices and Implications
Current Transplantation Reports (2018)